Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

Diabetes Obes Metab. 2024 Feb;26(2):758-762. doi: 10.1111/dom.15340. Epub 2023 Oct 26.
No abstract available

Keywords: canagliflozin; cardiovascular; clinical trials; heart failure; timing of benefits.

Publication types

  • Letter

MeSH terms

  • Canagliflozin / therapeutic use
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / prevention & control
  • Cardiovascular System*
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Heart Failure* / drug therapy
  • Humans
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • Canagliflozin
  • Sodium-Glucose Transporter 2 Inhibitors